Edition:
United Kingdom

Chiasma Inc (CHMA.OQ)

CHMA.OQ on NASDAQ Stock Exchange Global Select Market

6.15USD
9:00pm BST
Change (% chg)

$0.09 (+1.49%)
Prev Close
$6.06
Open
$6.08
Day's High
$6.25
Day's Low
$6.08
Volume
26,581
Avg. Vol
33,344
52-wk High
$7.15
52-wk Low
$1.20

Latest Key Developments (Source: Significant Developments)

Chiasma Q1 Loss Per Share $0.36
Thursday, 9 May 2019 

May 9 (Reuters) - Chiasma Inc ::CHIASMA REPORTS FIRST QUARTER 2019 RESULTS.Q1 LOSS PER SHARE $0.36.Q1 EARNINGS PER SHARE ESTIMATE $-0.34 -- REFINITIV IBES DATA.ADVANCING ITS ONGOING MULTI-NATIONAL MPOWERED™ PHASE 3 TRIAL.ENDED QUARTER WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $33.9 MILLION.  Full Article

Chiasma - Chiasma Optimal Phase 3 Topline Data Expected In Q3 2019
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Chiasma Inc ::CHIASMA INC - CHIASMA OPTIMAL PHASE 3 TOPLINE DATA EXPECTED IN Q3 2019.CHIASMA INC - ANTICIPATES SUBMITTING U.S. NDA BY YEAR-END 2019, ASSUMING POSITIVE CHIASMA OPTIMAL DATA.CHIASMA INC - PLAN FOR POSSIBLE FDA APPROVAL OF MYCAPSSA IN MID-2020.CHIASMA - ANTICIPATES CURRENT CASH BALANCE IS SUFFICIENT TO FUND OPERATIONS AS PLANNED THROUGH CHIASMA OPTIMAL TOPLINE DATA & INTO EARLY 2020.  Full Article

Chiasma Q3 Loss Per Share $0.31
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Chiasma Inc ::CHIASMA REPORTS THIRD QUARTER 2018 RESULTS.Q3 LOSS PER SHARE $0.31.CHIASMA - RANDOMIZES 80(TH) PATIENT IN PHASE 3 MPOWERED TRIAL OF OCTREOTIDE CAPSULES, ELECTS TO RESUME ENROLLMENT OF UP TO ADDITIONAL 15 U.S. PATIENTS.CHIASMA - CASH SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST ANTICIPATED RELEASE OF TOP-LINE CHIASMA OPTIMAL DATA WHILE SUPPORTING MPOWERED TRIAL.DECISION TO RESUME ENROLLMENT INTO MPOWERED TRIAL HAS NO EXPECTED IMPACT ON ONGOING CHIASMA OPTIMAL TRIAL.  Full Article

Chiasma Announces FDA Agreement To Redefine Certain Secondary Endpoints In Phase 3 Clinical Trial
Monday, 14 May 2018 

May 14 (Reuters) - Chiasma Inc ::CHIASMA ANNOUNCES FDA AGREEMENT TO REDEFINE CERTAIN SECONDARY ENDPOINTS IN CHIASMA OPTIMAL PHASE 3 CLINICAL TRIAL.CHIASMA - FOURTH, FIFTH SECONDARY ENDPOINTS IN PHASE 3 TRIAL NOW BEEN REDEFINED TO DESCRIPTIVE STATISTICS MEASURED WITHIN EACH TREATMENT GROUP.CHIASMA INC - UNDER SPA AGREEMENT MODIFICATION FOR CHIASMA OPTIMAL PHASE 3 TRIAL, BETWEEN-ARM COMPARISONS OF 2 DESCRIPTIVE MEASURES WILL NOT BE MADE.CHIASMA INC - FDA INDICATED IT PLANS TO CONSIDER SECONDARY ENDPOINTS IN ITS EVALUATION OF TOTALITY OF EVIDENCE OF ORAL OCTREOTIDE'S TREATMENT EFFECT.  Full Article

Chiasma Reports Q1 Loss Per Share $0.29
Thursday, 10 May 2018 

May 10 (Reuters) - Chiasma Inc ::CHIASMA REPORTS FIRST QUARTER 2018 RESULTS.Q1 LOSS PER SHARE $0.29.CHIASMA - EXPECTS EXISTING CASH, INVESTMENTS WILL BE SUFFICIENT TO FUND OPERATIONS THROUGH ANTICIPATED RELEASE OF DATA FROM CHIASMA OPTIMAL TRIAL BY 2019 END.  Full Article

Chiasma Inc Files For Mixed Shelf Of Up To $100 Million ‍​
Thursday, 22 Mar 2018 

March 22 (Reuters) - Chiasma Inc ::CHIASMA INC FILES FOR MIXED SHELF OF UP TO $100 MILLION – SEC FILING‍​.  Full Article

Chiasma Announces Expected Year-End 2017 Cash And Investments Balance Of About $67 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Chiasma Inc ::CHIASMA INC - ANNOUNCES EXPECTED YEAR-END 2017 CASH AND INVESTMENTS BALANCE OF APPROXIMATELY $67 MILLION.CHIASMA-EXISTING CASH TO BE SUFFICIENT TO FUND OPERATIONS THROUGH ANTICIPATED RELEASE OF TOP-LINE DATA FROM CHIASMA OPTIMAL PHASE 3 TRIAL BY 2019 END.  Full Article

Chiasma Q3 loss per share $0.28
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Chiasma Inc ::Chiasma reports third quarter 2017 results.Q3 loss per share $0.28.Chiasma Inc - ‍ cash, cash equivalents & marketable securities as of Sept 30, 2017 were $73.2 million, compared with $93.0 million as of December 31, 2016​.  Full Article

Chiasma announces first patient is randomized in phase 3 trial of Octreotide capsules in patients with acromegaly
Wednesday, 27 Sep 2017 

Sept 27 (Reuters) - Chiasma Inc :Chiasma announces first patient is randomized in phase 3 chiasma optimal clinical trial of Octreotide capsules in patients with acromegaly.Chiasma Inc - Meeting its previous guidance that enrollment in study would begin during second half of 2017​.Chiasma Inc - ‍Announced it has recently surpassed 50% patients randomized in its international phase 3 clinical trial​.  Full Article

Chiasma Q2 loss per share $0.28
Thursday, 10 Aug 2017 

Aug 10 (Reuters) - Chiasma Inc :Chiasma reports second quarter 2017 results.Q2 loss per share $0.28.Chiasma Inc - expect to have a cash and investment balance of at least $60 million at end of 2017.  Full Article